Humanitarian Use Device and Humanitarian Device Exemption regulatory programs: pros and cons.

Area of Science:

• Medical device regulation
• Rare disease therapeutics
• Health policy

Background:

• The US Food and Drug Administration (FDA) established the Humanitarian Use Device (HUD) and Humanitarian Device Exemption (HDE) program over a decade ago.
• The program aims to incentivize medical device firms to develop treatments for rare diseases.
• Limited peer-reviewed research exists on the effectiveness and practicalities of the HUD/HDE program.

Purpose of the Study:

• To analyze the differences between the HUD/HDE regulatory pathway and the standard system.
• To evaluate the potential benefits and drawbacks of the HUD/HDE program for device manufacturers.
• To forecast which humanitarian devices may reach the market in the next five years.

Main Methods:

• Conducted 40 semistructured interviews with stakeholders from firms that obtained HDE approval.
• Interviewees represented approximately 49% of firms with successful HDE-approved products.
• Gathered primary data on the experiences and perspectives of companies navigating the HUD/HDE program.

Main Results:

• Launching humanitarian devices involves short-term financial gains but can lead to long-term financial drains.
• Stakeholders provided insights into the practical challenges and rewards of the HUD/HDE program.
• The study identified key factors influencing the success and challenges of humanitarian device development.

Conclusions:

• The HUD/HDE program presents a complex regulatory landscape with both advantages and disadvantages for rare disease device development.
• Informed decision-making for sponsors is crucial for successful product development in this area.
• The findings aim to encourage further development of treatments for rare diseases through the HUD/HDE pathway.